Introduction {#dey306s13}
============

Controlled ovarian stimulation (COS) techniques that use gonadotropin-releasing hormone analogues are routinely used during IVF; however, COS often causes endocrine defects in the luteal phase, which may jeopardize embryo implantation and maintenance of early pregnancy ([@dey306C16]). As a result, luteal phase support is necessary to support embryo implantation and to enhance the probability of an ongoing pregnancy ([@dey306C19]). Progesterone has most commonly been used for luteal phase support and has been associated with an improvement in pregnancy rates in IVF treatment ([@dey306C19]; [@dey306C33]).

Various routes of progesterone administration for luteal phase support have been explored, with no single formulation or regimen identified as superior regarding efficacy ([@dey306C19]; [@dey306C33]). Progesterone for luteal phase support can be administered orally, intramuscularly, vaginally and most recently subcutaneously, with each route having different bioavailability and tolerability profiles ([@dey306C25]; [@dey306C28]; [@dey306C31]; [@dey306C24]). For instance, oral micronized progesterone has low bioavailability and is associated with systemic adverse events such as drowsiness, dizziness and headaches ([@dey306C28]; [@dey306C4]). In contrast, intramuscular progesterone is associated with injection-site pain and abscesses ([@dey306C28]; [@dey306C3]). Micronized vaginal progesterone (MVP) is now preferred over oral and intramuscular progesterone at most IVF centers, but it is associated with its own administration-related side effects such as vaginal irritation ([@dey306C31]; [@dey306C15]). MVP is usually administered as a gel or as capsules ([@dey306C31]), with both formulations having similar efficacy for luteal phase support ([@dey306C13]; [@dey306C26]; [@dey306C9]). Overall, there is a clinical need to provide a treatment that is efficacious, well tolerated, and easy to use, in order to improve patient satisfaction and treatment compliance among women undergoing IVF.

Dydrogesterone is a retroprogesterone that has been used since the 1960s for the treatment of conditions associated with progesterone deficiency ([@dey306C17]). Dydrogesterone is a more selective progesterone receptor agonist than progesterone, with lower affinity for androgen and glucocorticoid receptors ([@dey306C21]). Importantly, oral administration of dydrogesterone circumvents the inconvenience and side effects related to intravaginal or intramuscular administration ([@dey306C28]; [@dey306C3]; [@dey306C15]).

Numerous small-scale clinical trials and meta-analyses have indicated that dydrogesterone is at least as efficacious as MVP for luteal phase support ([@dey306C6]; [@dey306C18]; [@dey306C11]; [@dey306C32], [@dey306C33]; [@dey306C23]; [@dey306C29]; [@dey306C2]; [@dey306C22]; [@dey306C36]); however, a recent meta-analysis reported that the methodology of many of the studies was not optimal and the quality of the available evidence was judged low ([@dey306C33]). More recently, two new clinical studies (Lotus I and Lotus II) have been conducted for luteal phase support. The randomized, double-blind, double-dummy, Phase III study (Lotus I), conducted in 1031 women, demonstrated that oral dydrogesterone was non-inferior to MVP capsules in terms of pregnancy rates at 12 weeks of gestation following luteal phase support ([@dey306C30]). The objectives of this open-label, Phase III study (Lotus II) were to establish the non-inferiority of oral dydrogesterone versus MVP gel in terms of pregnancy rates at 12 weeks of gestation following luteal phase support, and to obtain safety and tolerability data. Since the publication of Lotus I and the completion of Lotus II, dydrogesterone has been approved for use in luteal support as part of assisted reproductive technology treatment in several countries.

Materials and Methods {#dey306s14}
=====================

Study design {#dey306s15}
------------

Lotus II, a randomized, open-label, multicenter, parallel-group, Phase III, non-inferiority study was conducted at 37 IVF centers in 10 countries (Australia, Belgium, China, Germany, Hong Kong, India, Russia, Singapore, Thailand and Ukraine) from 17 August 2015 until 26 May 2017. Lotus II was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Abbott Laboratories GmbH (or an authorized representative) or the investigator (according to national provisions) obtained written approval of the clinical study protocol (including amendments), the written subject informed consent form, informed consent updates, subject recruitment procedures and any other written information provided to subjects from an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), complying with the local regulatory requirements. Written approval of the study was obtained from the IEC/IRB before study commencement.

Participants {#dey306s16}
------------

Premenopausal women (\>18 to \<42 years of age) with a documented history of infertility who were planning to undergo IVF with or without ICSI, and who gave written informed consent, were enrolled in the study. Other key inclusion criteria included: absence of pregnancy; body mass index ≥18 to ≤30 kg/m^2^; early follicular phase (Days 2--4); FSH ≤15 IU/L and estradiol within normal clinical limits at screening; LH, prolactin (PRL), testosterone and thyroid-stimulating hormone (TSH) within normal clinical limits or not considered clinically significant within 6 months prior to or at screening; normal transvaginal ultrasound at screening (or within 14 days prior to screening); and single or double fresh embryo transfer. Key exclusion criteria included: evidence of head, ear, eye, nose, throat, cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine or neurologic/psychiatric disorders; allergy; recent major surgery (within 3 months); current or recent substance abuse, including that of alcohol and tobacco; history of chemotherapy; more than three unsuccessful IVF attempts; and history of recurrent pregnancy loss. The use of additional progesterone products was not permitted during the study.

During the study, there was a minor amendment to subject eligibility criteria. It became apparent that most Asian IVF centers were not routinely testing for LH, PRL, testosterone and TSH prior to IVF cycles. Therefore, the assessment of these hormones was added as a requirement at screening for those subjects who did not have available values.

Randomization and masking {#dey306s17}
-------------------------

The investigators enrolled the subjects; thereafter, the subjects were assigned to treatment groups using a centralized electronic system (Interactive Response Technology), which assigned a five-digit randomization number to each subject according to the randomization scheme provided by Clinical Supply Management of Abbott Healthcare Products B.V. Subjects were randomized 1:1 into the oral dydrogesterone or MVP gel treatment groups and were stratified by country and age group (\<35 and ≥35 years of age). Lotus II was open-label, as it was not technically feasible to make a placebo applicator for MVP gel.

Procedures {#dey306s18}
----------

During the screening process, subjects signed an informed consent form and the following parameters were analyzed: vital signs, concomitant medication, laboratory blood values, and pregnancy status (by transvaginal ultrasound if the last transvaginal examination was older than 14 days). On the day of oocyte retrieval (Day 1), subjects were randomly assigned to receive either oral dydrogesterone 10 mg tablets (Duphaston^®^; Abbott Biologicals, Netherlands) three times daily or 8% MVP gel 90 mg (Crinone^®^; Central Pharma Ltd, UK) once daily and luteal phase support was started. The dose of oral dydrogesterone for the Lotus clinical trial program was chosen based on the results of previous randomized controlled trials ([@dey306C6]; [@dey306C18]; [@dey306C11]), histological data ([@dey306C10]) and recommendations by IVF specialists.

Embryo transfer was performed on Day 3--6 after oocyte retrieval according to the clinic-specific IVF protocol. On Day 17--20 (Day 15 ± 3 after embryo transfer; 4 weeks of gestation), subjects had a pregnancy test (serum measurement of beta human chorionic gonadotropin). If pregnancy was confirmed on Day 43 ± 3 (Week 6; 8 weeks of gestation), luteal phase support was continued up to Day 71 ± 3 (Week 10; 12 weeks of gestation), at which point the presence of a fetal heartbeat was determined by transvaginal ultrasound. Treatment emergent adverse events (TEAEs) and concomitant treatment were recorded throughout the study. At delivery, gestational age and newborn parameters were obtained; 30 ± 3 days after delivery, the mother's and newborn's safety and wellbeing were recorded. The 10-week duration of luteal phase support was agreed by the Medical Evaluations Board to align with the dosing schedule of MVP capsules (Utrogestan^®^; Besins Healthcare, Belgium) used as the comparator in Lotus I ([@dey306C30]).

The safety sample included all randomized subjects who received at least one drug administration. The full analysis sample (FAS) consisted of all subjects in the safety sample who had a successful embryo transfer or discontinued before embryo transfer due to study drug-related issues. The per-protocol sample (PPS) consisted of all subjects in the FAS who did not present any major protocol deviations.

Outcomes {#dey306s19}
--------

The primary outcome was pregnancy rate at 12 weeks of gestation (Week 10 of treatment), as determined by a transvaginal ultrasound. Key secondary outcomes were: the frequency of positive pregnancy tests on Day 15 after embryo transfer, live birth rate and the number of healthy newborns. Newborn assessments included appearance, pulse, grimace, activity and respiration (APGAR) score; weight; height; head circumference; abnormal findings of physical examination; and any malformations. The safety outcomes were TEAEs and treatment-emergent serious adverse events (TESAEs) during the study period.

Statistical analyses {#dey306s20}
--------------------

Assuming a 35% pregnancy rate for both treatment groups based on previous studies and verification with an EU Health Authority, it was estimated that a sample size of 479 subjects per group would provide 90% power to demonstrate non-inferiority with a margin of 10%. Taking into account a 10% dropout rate, an overall sample size of 1066 subjects was planned.

The primary efficacy analysis consisted of constituting a two-sided 95% CI using the Cochran--Mantel--Haenszel test stratified for country and age group (\<35 and ≥35 years of age) estimating the difference in pregnancy rates between the two treatment groups and the normal distribution as approximation. Non-inferiority of dydrogesterone versus MVP gel was demonstrated if the lower bound of the 95% CI excluded a difference greater than the prespecified non-inferiority margin of −10%. The non-inferiority margin of −10% was chosen for clinical relevance and was agreed with the Medical Evaluations Board prior to initiating the Lotus program. The non-inferiority margin used in the Lotus program was the same as that used in two other recent Phase III studies of drugs now approved for luteal phase support in IVF (Endometrin^®^; Ferring Pharmaceuticals, USA and Prolutex^®^; IBSA Institut Biochimique SA, Switzerland) ([@dey306C9]; [@dey306C15]).

Pregnancy rates at Day 15 after embryo transfer and Day 43 (4 and 8 weeks of gestation) and live birth rates were analyzed using the same methods as for the primary efficacy analysis. Flow of subjects through the trial, demographics, concomitant medication and safety data were summarized by treatment group.

The study was registered at [ClinicalTrials.gov](ClinicalTrials.gov) (NCT02491437).

Results {#dey306s21}
=======

Between 17 August 2015 and 26 May 2017, 1225 subjects were enrolled in the study and 1034 subjects were randomized to receive oral dydrogesterone (*n* = 520) or MVP gel (*n* = 514); of these, 494 and 489 subjects were included in the FAS, and 490 and 481 subjects were included in the PPS, respectively (Fig. [1](#dey306F1){ref-type="fig"}). Overall, 32.3 and 30.5% of subjects in the dydrogesterone and MVP gel groups completed the study, respectively. The primary reason for discontinuing was pregnancy not confirmed at Day 15 after embryo transfer (48.7 and 52.9% of subjects in the oral dydrogesterone and MVP gel groups, respectively). Demographics and baseline characteristics are shown in Table [I](#dey306TB1){ref-type="table"} and were similar between the treatment groups. Subjects in the FAS were predominantly Asian or White (49.5 and 49.2%, respectively) and \<35 years of age (70.4%). Table ISubject demographics and baseline characteristics (FAS).Oral DYD (*N* = 494)MVP Gel (*N* = 489)All Subjects (*N* = 983)Mean age, years (SD)31.8 (4.4)31.6 (4.6)31.7 (4.5)Age category, *n* (%) \<35 years348 (70.4)344 (70.3)692 (70.4) ≥35 years146 (29.6)145 (29.7)291 (29.6)Race, *n* (%) Asian250 (50.6)237 (48.5)487 (49.5) Black1 (0.2)0 (0.0)1 (0.1) White237 (48.0)247 (50.5)484 (49.2) Other6 (1.2)5 (1.0)11 (1.1)Mean BMI, kg/m^2^ (SD)23.1 (3.1)23.1 (3.0)23.1 (3.0)Prior treatment, *n* (%)71 (14.4)61 (12.5)132 (13.4)[^1]

![Subject disposition (CONSORT flow diagram). ^a^Determined by inclusion/exclusion criteria. ^b^Three subjects in the oral dydrogesterone group were discontinued prior to embryo transfer due to study drug-related issues; these subjects were included in the FAS as failures. DYD, dydrogesterone; ET, embryo transfer; FAS, full analysis sample; IVF, in vitro fertilization; MVP, micronized vaginal progesterone; PPS, per-protocol sample; SS, safety sample.](dey306f01){#dey306F1}

The primary endpoint was met in both the FAS and PPS, with oral dydrogesterone achieving non-inferiority to MVP gel for pregnancy rate at 12 weeks of gestation. For the oral dydrogesterone and MVP gel groups, pregnancy rates at 12 weeks of gestation were 38.7 and 35.0% in the FAS (adjusted difference, 3.7%; 95% CI: −2.3 to 9.7), and 36.7 and 34.7% in the PPS (adjusted difference, 2.0%; 95% CI: −4.0 to 8.0), respectively (Fig. [2](#dey306F2){ref-type="fig"}). As the lower-bound CIs were greater than the non-inferiority margin of −10%, non-inferiority of oral dydrogesterone versus MVP gel was demonstrated in both the FAS and PPS. As prespecified in the protocol, the primary endpoint was adjusted for country and age; no relevant interaction was observed between the treatment and country or age group. Analysis of subjects in the FAS who underwent a single embryo transfer identified comparable pregnancy rates at 12 weeks of gestation between the oral dydrogesterone and MVP gel groups (adjusted difference, 0.4%; 95% CI: −10.0 to 10.8). In subjects who underwent a double embryo transfer, pregnancy rates at 12 weeks of gestation were also comparable in the oral dydrogesterone group compared with the MVP gel group (adjusted difference, 5.3%; 95% CI: −2.2 to 12.7).

![Pregnancy and live birth rates post-treatment. Pregnancy rates at 4, 8 and 12 weeks of gestation, and the live birth rates (all statistically adjusted for country and age group) are shown for the FAS and PPS. A non-inferiority margin of 10% was used, whereby the test drug is non-inferior to the comparator if the lower-bound 95% CI excludes a difference greater than −10%. ^a^Denominators: Four subjects were removed from the oral dydrogesterone PPS (*N* = 490) compared with the FAS (*N* = 494) because all four subjects had more than three IVF attempts, which was an exclusion criterion. ^b^Nominators at 12 weeks of gestation (primary endpoint): Eleven subjects were removed from the oral dydrogesterone PPS (*n* = 180) compared with the FAS (*n* = 191) because nine pregnant subjects took additional progesterone before 12 weeks of gestation (counted as success in FAS, but failure in PPS), and two subjects had major protocol deviations (excluded from the PPS). ^c^Denominators: Eight subjects were removed from the MVP gel PPS (*N* = 481) compared with the FAS (*N* = 489) because seven subjects had more than three IVF attempts, which was an exclusion criterion, and one additional subject did not meet the inclusion criteria. ^d^Nominators at 12 weeks of gestation (primary endpoint): Four subjects were removed from the MVP gel PPS (*n* = 167) compared with the FAS (*n* = 171) because three pregnant subjects took additional progesterone before 12 weeks of gestation (counted as success in FAS, but failure in PPS), and one subject had a major protocol deviation (excluded from the PPS). CI, confidence interval; DYD, dydrogesterone; FAS, full analysis sample; IVF, in vitro fertilization; MVP, micronized vaginal progesterone; PPS, per-protocol sample.](dey306f02){#dey306F2}

At 4 weeks of gestation, adjusted differences in pregnancy rates between the oral dydrogesterone and MVP gel groups were 3.6% (95% CI: −2.6 to 9.8) in the FAS and 2.9% (95% CI: −3.4 to 9.1) in the PPS; at 8 weeks of gestation, these values were 3.9% (95% CI: −2.2 to 9.9) in the FAS and 2.4% (95% CI: −3.7 to 8.5) in the PPS (Fig. [2](#dey306F2){ref-type="fig"}). In the FAS between 4 and 12 weeks of gestation, pregnancy rates in the oral dydrogesterone and MVP gel groups decreased by 8.7 and 8.8%, respectively, suggesting a comparable miscarriage rate in the two treatment groups during this time frame.

Live birth rates of 34.4 and 32.5% in the FAS (adjusted difference, 1.9%; 95% CI: −4.0 to 7.8), and 34.3 and 32.9% in the PPS (adjusted difference, 1.5%; 95% CI: −4.5 to 7.4), were obtained for the oral dydrogesterone and MVP gel groups, respectively (Fig. [2](#dey306F2){ref-type="fig"}).

The course and outcomes of pregnancy in subjects treated with oral dydrogesterone or MVP gel are summarized in Table [II](#dey306TB2){ref-type="table"}. The number of embryos transferred was similar between the treatment groups, as was the number of newborns and the proportion of single and multiple births. Table IICourse and outcomes of pregnancy in subjects (FAS).Oral DYDMVP GelAllSubjects who underwent embryo transfer, *n*491^a^489980Subjects who underwent embryo transfer after ICSI, *n* (%)321 (65.4)304 (62.2)625 (63.8)Day of embryo transfer after oocyte retrieval, *n* (%) \<5 days319 (65.0)286 (58.5)605 (61.7) ≥5 days172 (35.0)203 (41.5)375 (38.3)Number of embryos transferred, *n* (%) 1162 (33.0)164 (33.5)326 (33.3) 2324 (66.0)324 (66.3)648 (66.1) \>25 (1.0)1 (0.2)6 (0.6)Subjects who had at least one newborn, *n* (%)^b^170 (34.6)159 (32.5)329 (33.6)Total number of newborns, *n*205188393 One newborn infant, *n* (%)^c^135 (79.4)131 (82.4)266 (80.9) Two newborn infants, *n* (%)^c^35 (20.6)27 (17.0)62 (18.8) More than two newborn infants, *n* (%)^c^0 (0.0)1 (0.6)1 (0.3)[^2][^3][^4][^5]

The proportions of subjects with at least one TEAE in the oral dydrogesterone and MVP gel groups were 53.1 and 48.6%, respectively. The proportions of severe TEAEs and TESAEs were low in both treatment groups (severe TEAEs: 7.3 and 6.8%; TESAEs: 13.7 and 13.1% of subjects in the oral dydrogesterone and MVP gel groups, respectively). There were no maternal deaths in either treatment group. The proportions of TEAEs leading to study termination in the oral dydrogesterone and MVP gel groups were 12.4 and 11.1%, respectively (Table [III](#dey306TB3){ref-type="table"}). Only 6.0 and 5.9% of TEAEs in the oral dydrogesterone and MVP gel groups, respectively, were reported by the investigators as having a reasonable possibility of a causal relationship with the study drug. The most common TEAE was vaginal hemorrhage, which was reported by 9.8% of subjects in the oral dydrogesterone group and 7.2% of subjects in the MVP gel group. The incidence of vulvovaginal signs and symptoms was low in both groups (vaginal discharge, 2.1 and 0.6%; vulvovaginal discomfort, 0.0 and 0.8%; vulvovaginal pruritus, 0.2 and 0.4% of subjects in the oral dydrogesterone and MVP gel groups, respectively) (Table [III](#dey306TB3){ref-type="table"}). Table IIIMaternal and fetal/neonatal TEAEs.Oral DYD (*N* = 518)MVP Gel (*N* = 512)All (*N* = 1030)Maternal population, n (%)^a^ All TEAEs275 (53.1)249 (48.6)524 (50.9)  At least one TESAE71 (13.7)67 (13.1)138 (13.4)  At least one severe TEAE38 (7.3)35 (6.8)73 (7.1)  TEAEs leading to study termination64 (12.4)57 (11.1)121 (11.7)  Deaths (maternal)0 (0.0)0 (0.0)0 (0.0) Vascular disorders12 (2.3)9 (1.8)21 (2.0)  Peripheral embolism and thrombosis1 (0.2)1 (0.2)2 (0.2) Reproductive system and breast disorders89 (17.2)82 (16.0)171 (16.6)  Vaginal hemorrhage51 (9.8)37 (7.2)88 (8.5) Gastrointestinal disorders69 (13.3)67 (13.1)136 (13.2) Nervous system disorders19 (3.7)19 (3.7)38 (3.7) Vulvovaginal signs and symptoms11 (2.1)9 (1.8)20 (1.9)  Vaginal discharge11 (2.1)3 (0.6)14 (1.4)  Vulvovaginal discomfort0 (0.0)4 (0.8)4 (0.4)  Vulvovaginal pruritus1 (0.2)2 (0.4)3 (0.3)Oral DYD (*N* = 221)MVP Gel (*N* = 201)All (*N* = 422)Fetal/neonatal population, n (%)^b^ At least one TESAE28 (12.7)23 (11.4)51 (12.1) TEAEs of special interest: congenital,    familial and genetic disorders14 (6.3)10 (5.0)24 (5.7)  Atrial septal defect5 (2.3)7 (3.5)12 (2.8)  Heart disease congenital2 (0.9)4 (2.0)6 (1.4)  Patent ductus arteriosus1 (0.5)4 (2.0)5 (1.2)  Congenital aortic anomaly0 (0.0)1 (0.5)1 (0.2)  Accessory auricle1 (0.5)0 (0.0)1 (0.2)  Amniotic band syndrome1 (0.5)0 (0.0)1 (0.2)  Congenital central nervous system anomaly1 (0.5)0 (0.0)1 (0.2)  Congenital cystic kidney disease1 (0.5)0 (0.0)1 (0.2)  Congenital hand malformation1 (0.5)0 (0.0)1 (0.2)  Cystic lymphangioma1 (0.5)0 (0.0)1 (0.2)  Intestinal malrotation1 (0.5)0 (0.0)1 (0.2)  Kinematic imbalances1 (0.5)0 (0.0)1 (0.2)  Renal dysplasia1 (0.5)0 (0.0)1 (0.2)  Turner's syndrome1 (0.5)0 (0.0)1 (0.2)[^6][^7][^8]

The most common TESAEs occurring in \>1% of subjects in either treatment group were missed abortion (2.3 and 0.4% of subjects in the oral dydrogesterone and MVP gel groups, respectively) and ovarian hyperstimulation (2.1 and 2.7% of subjects in the oral dydrogesterone and MVP gel groups, respectively). Further analysis of all TEAEs related to abortion revealed a comparable overall incidence between the two treatment groups. The most common TESAEs with a reasonable possibility of a causal relationship with the study drugs were vaginal hemorrhage (1.2 and 1.4% of subjects, respectively), hepatic function abnormal (1.0 and 0.4% of subjects, respectively) and vaginal discharge (1.0 and 0.0% of subjects, respectively). Overall, the safety and tolerability data were generally similar between the treatment groups.

The proportion of fetuses/newborns with at least one TESAE was 12.7% in the oral dydrogesterone group and 11.4% in the MVP gel group. The incidence of TEAEs of special interest (congenital, familial, and genetic disorders) was low and comparable between treatment groups (6.3 and 5.0% in the oral dydrogesterone and MVP gel groups, respectively); of these, the most common was atrial septal defects (2.3 and 3.5% in the oral dydrogesterone and MVP gel groups, respectively) (Table [III](#dey306TB3){ref-type="table"}). Overall, the incidence of fetuses/newborns with congenital heart malformations was low in both treatment groups: 2.7% (6/221) and 5.0% (10/201) in the oral dydrogesterone and MVP gel groups, respectively (five fetuses/newborns had more than one anomaly; two in the oral dydrogesterone group and three in the MVP gel group).

In most cases in both treatment groups, no abnormal findings were found from the physical examination of newborns at delivery (92.2 and 93.5% of newborns in the oral dydrogesterone and MVP gel groups, respectively). The mean ±SD weight of newborns was similar in the two treatment groups (2.9 ± 0.7 kg and 3.0 ± 0.7 kg in the oral dydrogesterone and MVP gel groups, respectively). Height, head circumference and APGAR score were comparable between the treatment groups (Table [IV](#dey306TB4){ref-type="table"}). Table IVNewborn characteristics (FAS).Oral DYD (*N* = 494)MVP Gel (*N* = 489)Newborns, *n*205188Gender, *n* (%) Male105 (51.2)95 (50.5) Female100 (48.8)93 (49.5)Abnormal findings of physical examination,   *n* (%) Yes16 (7.8)12 (6.5) No188 (92.2)173 (93.5) Missing13Height, cm (mean ± SD)48.8 ± 4.048.8 ± 3.9Weight, kg (mean ± SD)2.9 ± 0.73.0 ± 0.7Head circumference, cm (mean ± SD)33.6 ± 2.533.9 ± 2.6APGAR score (mean ± SD) 1 min postpartal8.7 ± 1.28.5 ± 1.4 5 min postpartal9.3 ± 1.19.3 ± 0.9[^9]

Discussion {#dey306s22}
==========

The Lotus II study demonstrated that oral dydrogesterone was non-inferior to MVP gel for luteal phase support in fresh-cycle IVF. Analysis of the primary endpoint (presence of a fetal heartbeat at 12 weeks of gestation) and secondary endpoints (pregnancy rates at 4 and 8 weeks of gestation, live birth rates and number of healthy newborns) showed that results were comparable between the treatment groups. Although miscarriage rates were not investigated as a direct endpoint of the study, similar decreases in pregnancy rates between 4 and 12 weeks of gestation were observed in the two treatment groups, suggesting comparable miscarriage rates. Overall, these findings were consistent with the results of the Lotus I study, which demonstrated that oral dydrogesterone was non-inferior to MVP capsules in terms of pregnancy rates at 12 weeks of gestation following luteal phase support ([@dey306C30]). The results from Lotus I and Lotus II, a substantial study program in IVF, demonstrate that oral dydrogesterone is a viable alternative to two of the main types of MVP (gel or capsules) for luteal phase support.

Lotus I and Lotus II also demonstrated that oral dydrogesterone and MVP had comparable safety and tolerability profiles. Of note, the overall incidence of abortion-related TEAEs between the two treatment groups were comparable. Furthermore, the incidence of congenital, familial and genetic disorders from Lotus II (6.3 and 5.0% in the oral dydrogesterone and MVP gel groups, respectively) was comparable to that from an analysis of 308 974 births ([@dey306C8]). Importantly, the percentage of fetuses/newborns with congenital heart malformations was 2.7% (6/221) and 5.0% (10/201) in the oral dydrogesterone and MVP gel groups, respectively. Although a previous retrospective case-controlled study reported a positive association between congenital heart malformations and dydrogesterone ([@dey306C34]), the study did not implement key principles to reduce selection, confounding and information bias; therefore, no evidence of a causal relationship can be concluded from the analysis.

Overall, the robust Lotus I and Lotus II studies identified no new safety concerns associated with using oral dydrogesterone, and no link to congenital malformations could be identified. However, investigating the long-term safety of progestogen formulations for luteal phase support will be an important area of future research. While Lotus I and Lotus II assessed the tolerability of oral dydrogesterone and MVP capsules and gel through documentation of TEAEs, these studies were not designed to investigate patient preferences for each treatment. However, it has been well documented that oral administration is preferred by patients over intravaginal application ([@dey306C5]; [@dey306C1]; [@dey306C6]).

Although both Lotus studies were methodologically robust, the authors acknowledge some limitations. Lotus II had an open-label study design; it was not possible to perform a double-blind and double-dummy study because it was not technically feasible to make a placebo applicator for MVP gel. The open-label study design increased the risk of bias for subjective endpoints, which could potentially influence the collection of tolerability data. For example, patients may report known side effects, and if subjective tolerability questions were not asked systematically to all patients, bias could be introduced. However, there can be little to no bias expected for the objective endpoints evaluated in this study, such as pregnancy rates at 12 weeks of gestation as determined by a transvaginal ultrasound, live birth rates or analyses of liver enzymes.

Another potential limitation of the study could include the 10-week treatment period of the Lotus program, which was based on the dosing schedule for MVP capsules (Utrogestan^®^; Besins Healthcare, Belgium): the comparator used in Lotus I ([@dey306C30]). However, while there is evidence to suggest that a shorter duration of treatment is effective ([@dey306C14]), the optimal dosing schedule and period of luteal phase support with progestogens remains to be established ([@dey306C19]). Finally, subjects with more than three unsuccessful IVF attempts and those with recurrent pregnancy loss were excluded from the study, due to the low pregnancy rates in these populations and the subsequent need for further stratification of the results.

The large sample size and the multicenter study design of Lotus II positively impacts on the generalizability of the results. However, as in all clinical trials in selected patient populations, generalizability of the findings may be limited by patient factors. For example, it has been established that increasing body mass index and increasing age are associated with decreased clinical pregnancy rates from IVF ([@dey306C27]), and are factors that could affect generalizability. In this study, it is important to note that subjects were included if they had a body mass index within the range of ≥18 to ≤30 kg/m^2^, and 70.4% of included subjects were \<35 years of age.

While the results from Lotus I, Lotus II and several smaller clinical studies demonstrate the efficacy of oral dydrogesterone for luteal phase support in fresh-cycle IVF ([@dey306C6]; [@dey306C18]; [@dey306C11]; [@dey306C23]; [@dey306C29]; [@dey306C22]; [@dey306C36]; [@dey306C30]), limited data are available about its use in programmed frozen-thawed cycles. In contrast to fresh cycles, the absence of corpora lutea in programmed frozen-thawed cycles means that the endometrium is totally dependent on exogenous progestogen supplementation ([@dey306C12]). Although two small randomized clinical studies have investigated the use of oral dydrogesterone for luteal phase support in programmed frozen-thawed cycles ([@dey306C20]; [@dey306C35]), further studies are needed to establish the efficacy of oral dydrogesterone in this setting.

Overall, the results from Lotus I and Lotus II demonstrate that oral dydrogesterone is as efficacious as MVP (capsules or gel) for luteal phase support in fresh-cycle IVF, with a similar safety profile within the studies. Therefore, because of its patient-friendly oral administration route, dydrogesterone has the potential to induce a paradigm shift for luteal phase support in the estimated 1.5 million women undergoing IVF each year ([@dey306C7]).
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[^1]: BMI, body mass index; DYD, dydrogesterone; FAS, full analysis sample; MVP, micronized vaginal progesterone; SD, standard deviation.

[^2]: DYD, dydrogesterone; FAS, full analysis sample; ICSI, intracytoplasmic sperm injection; MVP, micronized vaginal progesterone.

[^3]: ^a^Three subjects in the oral dydrogesterone group were discontinued prior to embryo transfer.

[^4]: ^b^Percentages calculated according to the number of subjects in the FAS who underwent embryo transfer.

[^5]: ^c^Percentages calculated according to the number of subjects who had at least one newborn.

[^6]: DYD, dydrogesterone; MVP, micronized vaginal progesterone; TEAE, treatment-emergent adverse event; TESAE, treatment-emergent serious adverse event.

[^7]: ^a^Safety sample.

[^8]: ^b^Percentages calculated based on the fetal/neonatal population, which included 16 and 13 miscarriages or stillbirths in the oral dydrogesterone and MVP gel groups, respectively.

[^9]: APGAR, appearance, pulse, grimace, activity, and respiration; DYD, dydrogesterone; FAS, full analysis sample; MVP, micronized vaginal progesterone; SD, standard deviation.
